Analysts See $-0.13 EPS for Capricor Therapeutics, Inc. (CAPR)

July 21, 2018 - By Theresa Judd

Capricor Therapeutics, Inc. (NASDAQ:CAPR) LogoInvestors sentiment decreased to 0.44 in 2018 Q1. Its down 3.89, from 4.33 in 2017Q4. It worsened, as 4 investors sold Capricor Therapeutics, Inc. shares while 5 reduced holdings. 3 funds opened positions while 1 raised stakes. 1.04 million shares or 76.59% less from 4.44 million shares in 2017Q4 were reported.
Northern reported 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Perceptive Advsrs Llc holds 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR) or 4,000 shares. Bank & Trust Of America Corp De reported 5,500 shares. Morgan Stanley invested in 0% or 2 shares. Vanguard Grp has 712,533 shares. Royal National Bank & Trust Of Canada has 232 shares for 0% of their portfolio. Geode Cap Lc has 76,996 shares for 0% of their portfolio. Virtu Limited Liability stated it has 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Acadian Asset Management Ltd Liability invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). National Bank Of Mellon owns 26,762 shares. Blackrock Inc invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Architects holds 0% or 2,000 shares in its portfolio. Deutsche Bancshares Ag holds 0% or 600 shares. Apriem Advsr accumulated 50,000 shares. Cordasco Fincl Network reported 3,100 shares.

Analysts expect Capricor Therapeutics, Inc. (NASDAQ:CAPR) to report $-0.13 EPS on August, 9.They anticipate $0.03 EPS change or 18.75 % from last quarter’s $-0.16 EPS. After having $-0.14 EPS previously, Capricor Therapeutics, Inc.’s analysts see -7.14 % EPS growth. The stock decreased 1.49% or $0.02 during the last trading session, reaching $1.32. About 188,492 shares traded. Capricor Therapeutics, Inc. (NASDAQ:CAPR) has risen 61.45% since July 21, 2017 and is uptrending. It has outperformed by 48.88% the S&P500.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Ratings Coverage

Among 2 analysts covering Capricor Therapeutics (NASDAQ:CAPR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Capricor Therapeutics had 4 analyst reports since January 26, 2018 according to SRatingsIntel. H.C. Wainwright maintained Capricor Therapeutics, Inc. (NASDAQ:CAPR) on Friday, January 26 with “Buy” rating. The company was maintained on Friday, May 11 by H.C. Wainwright. The company was maintained on Thursday, March 29 by H.C. Wainwright.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company has market cap of $38.43 million. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. It has a 15.53 P/E ratio.

More important recent Capricor Therapeutics, Inc. (NASDAQ:CAPR) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on July 13, 2018, also Nasdaq.com published article titled: “Capricor Therapeutics and PPMD to Host Webinar for Duchenne Muscular Dystrophy Community on July 18”, Benzinga.com published: “Benzinga Pro’s 5 Stocks To Watch Today” on July 17, 2018. More interesting news about Capricor Therapeutics, Inc. (NASDAQ:CAPR) was released by: Globenewswire.com and their article: “Capricor Therapeutics to Present at PPMD Annual Conference” with publication date: June 28, 2018.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.